Mycobacterial shikimate pathway enzymes as targets for drug design

R. G. Ducati, Luiz A. Basso, Diogenes S. Santos

Research output: Contribution to journalReview articlepeer-review

66 Scopus citations


The aetiological agent of tuberculosis (TB), Mycobacterium tuberculosis, is responsible for millions of deaths annually. The increasing prevalence of the disease, the emergence of multidrug-resistant strains, and the devastating effect of human immunodeficiency virus co-infection have led to an urgent need for the development of new and more efficient antimycobacterial drugs. Since the shikimate pathway is present and essential in algae, higher plants, bacteria, and fungi, but absent from mammals, the gene products of the common pathway might represent attractive targets for the development of new antimycobacterial agents. In this review we describe studies on shikimate pathway enzymes, including enzyme kinetics and structural data. We have focused on mycobacterial shikimate pathway enzymes as potential targets for the development of new anti-TB agents.

Original languageEnglish (US)
Pages (from-to)423-435
Number of pages13
JournalCurrent drug targets
Issue number3
StatePublished - Mar 2007
Externally publishedYes


  • 3-dehydroquinate dehydratase
  • 3-dehydroquinate synthase
  • 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase
  • 5-enolpyruvylshikimate-3-phosphate synthase
  • Antimycobacterialdrug design
  • Chorismate synthase
  • Shikimate 5-dehydrogenase
  • Shikimate kinase

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Mycobacterial shikimate pathway enzymes as targets for drug design'. Together they form a unique fingerprint.

Cite this